Home > Insider Trading > Filing (0000947871-16-001218)

Filing Details

Accession Number:: 0000947871-16-001218
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-05-25 18:45:18
Reporting Period:: 2016-05-20

Filing Date:: 2016-05-25
Accepted Time:: 2016-05-25 18:45:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1621227	Adaptimmune Therapeutics Plc	ADAP	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1357522	A. Peter Thompson	C/O Adaptimmune Therapeutics Plc 101 Park Drive, Milton Park Abingdon, Oxfordshire X0 OX14 4RY		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares With A Nominal Value Of Gbp0.001 Per Share	Acquisiton	2016-05-20	2,400	$10.04	28,043,404	No	4	P	Indirect	See Footnotes
Ordinary Shares With A Nominal Value Of Gbp0.001 Per Share	Acquisiton	2016-05-23	1,191,600	$10.40	29,235,004	No	4	P	Indirect	See Footnotes
Ordinary Shares With A Nominal Value Of Gbp0.001 Per Share	Acquisiton	2016-05-24	518,400	$10.48	29,753,404	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes
No	4	P	Indirect	See Footnotes

Footnotes

The ordinary shares whose purchase is reported on this line are represented by American Depositary Shares ("ADSs") and are held of record by OrbiMed Private Investments V, LP ("OPI V"). Each ADS represents six ordinary shares of Adaptimmune Therapeutics plc. Of the amount of securities reported in column 5, OPI V holds 25,408,300 shares directly in the form of ordinary shares, and the balance of the ordinary shares are represented by ADSs.
The price reported in Column 4 is a weighted average price. These shares of the Issuer's common stock ("Shares") were purchased in multiple transactions at prices ranging from $10.03 to $10.05 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the Securities and Exchange Commission (the "SEC") full information regarding the Shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $10.15 to $10.55 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $10.45 to $10.52 inclusive. Upon request, the Reporting Persons undertake to provide the Issuer, any security holder of the Issuer, or the SEC full information regarding the Shares purchased at each separate price within the range set forth in this footnote.
These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the sole general partner of OPI V, and OrbiMed Advisors LLC ("Advisors"), a registered adviser under the Investment Advisors Act of 1940, as amended, is the sole managing member of GP V. Samuel D. Isaly ("Isaly"), a natural person, is the managing member of, and holder of a controlling interest in, Advisors. By virtue of such relationships, GP V, Advisors and Isaly may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Person is an employee of Advisors.
Each of GP V, Advisors, Isaly and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any such entity or person, including the Reporting Person, is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.